News

An anonymous, online survey was conducted through HS support groups from June 2022 to July 2022.

Study authors found that injection with a needle resulted in a higher incidence of ecchymosis.

AbbVie announced that patients treated with risankizumab achieved significantly higher results than those given apremilast.

Researchers found that lipid profile levels were higher in patients with acne vulgaris compared to otherwise healthy patients.

This week’s collection of the latest dermatologic studies covers benzoyl peroxide gel with oral doxycycline compared to lymecycline, interactions between the aesthetic device industry and dermatologists, nasal soft tissue pliability, and Merkel cell carcinoma in situ with reticulated infundibulocystic proliferation.

Furthermore, a survey showed that more than half of providers do not discuss clothing modifications, and half report providing patients with wound care supplies that are covered by insurance.

Quality of life is impacted far beyond the physical challenges for those with oculocutaneous albinism.

Researchers found that treatment for atopic dermatitis could contribute to a higher mutation rate.

Programs will address an education or care gap in skin of color that is not being met in dermatological care.

Using hand washing and alcohol-based hand sanitizer use during the COVID-19 pandemic as a baseline, researchers evaluated the effects of these behaviors on the skin’s microbiome.

LiVDerm and the Masters of Pediatric Dermatology Symposium have developed a 6-module course that covers some of the most common skin care conditions in pediatric patients.

Click here to answer this week's poll.

Researchers noted that serum levels of malondialdehyde and vitamin C are indicators of the impairment caused by systemic oxidative stress.

In this month's Cosmetic Conundrums column, Zoe Diana Draelos, MD, reviews recent advances in cosmetics and the illusions they create.

In the PERSIST study, improvements were sustained through week 104.

Both therapies for alopecia areata and completely resected stage IIB/C melanoma could be approved by the EC for patients aged 12 years or older.

AbbVie announced that treatment has begun in the first randomized, placebo-controlled, double-blind, multicenter study.

A study found that maternal alopecia areata led to a significantly higher incidence of childhood development of autoimmune, psychiatric, thyroid, and other disorders.

Daphne Chan, PhD, MHEcon, discusses the Pathways program, a partnership between the AAD, Janssen, and Kenvue to mentor young, aspiring dermatology providers.

Understanding the underlying motivation for seeking out minimally invasive cosmetic procedures is important to provide individualized and holistic care to patients.

Keep up with the latest headlines in dermatology from the past week, including Novan, Inc.'s bankruptcy filing, rates of melanoma in European Union countries, and more.

ICYMI, this week we had stories about managing Merkel cell carcinoma in patients with skin of color, addressing disparities in atopic dermatitis with telehealth, ruxolitinib for rapid pruritus reduction, and more.

Verrica’s VP-102 is the first FDA-approved treatment for molluscum lesions.

FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.

Researchers applied EB-101, a new cell therapy, to patients with recessive dystrophic epidermolysis bullosa with positive results.

Grant applications are open from now until August 24, 2023, with an anticipated project start/end date of January 2024 through July 2025.

A recent study found no correlation between a genetic predisposition to psoriasis or systemic treatment for psoriasis and an increase in the severity of COVID-19 illness.

Study results are expected to be presented at international dermatology conferences by the end of the year.

Compared to patients who identified as heterosexual, patients in the LGBTQ+ community have a higher prevalence of atopic dermatitis, asthma, and allergic rhinitis.

Introducing our newest weekly series, the Journal Digest, a collection of trending studies from leading dermatology journals. This week’s first edition covers IVIg treatment for autoimmune bullous dermatoses, body-focused repetitive behaviors, hormonal treatments for HS, dupilumab and skin barrier function, and a 2023 alopecia areata update.